A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain - the NOVA Trial
Gesynta Pharma AB
190 participants
Oct 15, 2025
INTERVENTIONAL
Conditions
Summary
The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive vipoglanstat capsules orally for approximately 4 menstrual cycles during the treatment period.
Participants will receive matching placebo capsules orally for approximately 4 menstrual cycles during the treatment period.
Locations(41)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07260669